美沙酮,临床注释,变异和临床注释数据

id	等位基因	注释文本
279	*1xN	Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.
278	*1	Patients carrying the CYP2D61 allele in combination with an increased function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the 1 allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles, but increased concentrations of methadone as compared to patients carrying a normal function allele in combination with an increased function allele. Patients carrying the *1 allele in combination with a no function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.
100	*6	Patients carrying the CYP2D6*6 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.
99	*4	Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.
98	*3	Patients carrying the CYP2D6*3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.

等位基因

注释文本

Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.

278

Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *1 allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles, but increased concentrations of methadone as compared to patients carrying a normal function allele in combination with an increased function allele. Patients carrying the *1 allele in combination with a no function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.

100

Patients carrying the CYP2D6*6 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.

Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.

Patients carrying the CYP2D6*3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.

id	证据的ID	总结
14551	1451161540	CYP2D6 1/2xN + 2/2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.
14550	1451228801	CYP2D6 1/3 + 1/4 + 1/5 + 1/6 + 4/5 are not associated with concentrations of methadone as compared to CYP2D6 1/1.
14549	1451156440	CYP2D6 3/4 + 4/4 are not associated with concentrations of methadone as compared to CYP2D6 1/1 + 1/3 + 1/4.
14548	1451153742	CYP2D6 3/4 + 4/4 + 4/6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 1/1 + 1/3 + 1/4 + 1/5 + 1/6 (assigned as normal metabolizer genotype phenotype) .
14547	1451153720	CYP2D6 1/1xN is associated with decreased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 1/1 + 1/3 + 1/4 + 1/5 + 1/6 (assigned as normal metabolizer genotype phenotype) .
14546	1451158020	CYP2D6 poor metabolizer phenotype is not associated with trough concentration of methadone as compared to CYP2D6 normal metabolizer phenotype.
14545	1450374166	CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.
14544	1450374142	CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (R)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.
14543	1449266567	CYP2D6 poor metabolizer genotype is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.
14542	1449266559	CYP2D6 ultrarapid metabolizer genotype is associated with decreased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.

证据的ID

总结

14551

1451161540

CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.

14550

1451228801

CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*5 are not associated with concentrations of methadone as compared to CYP2D6 *1/*1.

14549

1451156440

CYP2D6 *3/*4 + *4/*4 are not associated with concentrations of methadone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.

14548

1451153742

CYP2D6 *3/*4 + *4/*4 + *4/*6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .

14547

1451153720

CYP2D6 *1/*1xN is associated with decreased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer genotype phenotype) .

14546

1451158020

CYP2D6 poor metabolizer phenotype is not associated with trough concentration of methadone as compared to CYP2D6 normal metabolizer phenotype.

14545

1450374166

CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.

14544

1450374142

CYP2D6 poor and ultrarapid metabolizers are not associated with concentrations of (R)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.

14543

1449266567

CYP2D6 poor metabolizer genotype is not associated with concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.

14542

1449266559

CYP2D6 ultrarapid metabolizer genotype is associated with decreased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2D6 intermediate metabolizer and normal metabolizer.

id	类型	评论
28	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
27	Update	Edited phenotype descriptions to include CPIC 'no recommendation'.
26	Update	Added PMID 28723731 to evidence and edited phenotype descriptions
25	Update	Added PMID 21589866 to evidence and updated phenotype descriptions
24	Update	Added PMID 19133059 to evidence
23	Update	Added PMID 17502774 to evidence
22	Create	Created

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:33068302000535
　医药代理商群１：

医药代理商群２：

医药代理商群３：

最新招商产品更多>>